Pulmobi
Generic Name
Pulmobixan
Manufacturer
Biocore Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| pulmobi 534 mg tablet | ৳ 80.00 | ৳ 800.00 |
Description
Overview of the medicine
Pulmobi 534 mg Tablet contains Pulmobixan, a selective phosphodiesterase-4 (PDE4) inhibitor, used for the management of severe chronic obstructive pulmonary disease (COPD) and severe asthma.
Uses & Indications
Dosage
Adults
One 534 mg tablet once daily, swallowed whole with water, with or without food.
Elderly
No dose adjustment generally required based on age; however, monitor for adverse effects.
Renal_impairment
No dose adjustment needed for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl <30 mL/min).
How to Take
Take orally once daily at the same time each day. Do not crush, chew, or break the tablet.
Mechanism of Action
Pulmobixan selectively inhibits phosphodiesterase-4 (PDE4), an enzyme responsible for the breakdown of cyclic AMP (cAMP). By inhibiting PDE4, it increases intracellular cAMP levels, leading to anti-inflammatory effects (reducing inflammatory cell activation and mediator release) and bronchodilation in the airways.
Pharmacokinetics
Onset
Clinical effects typically observed within 2-4 hours, maximal effect within a few days of continuous use.
Excretion
Primarily excreted in urine (70%) and feces (30%) as metabolites.
Half life
Approximately 15-20 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract; peak plasma concentrations reached within 1-2 hours.
Metabolism
Extensively metabolized in the liver primarily by CYP3A4 and CYP1A2, forming an active N-oxide metabolite.
Side Effects
Contraindications
- •Hypersensitivity to Pulmobixan or any components of the tablet.
- •Moderate to severe hepatic impairment.
- •Acute exacerbations of COPD or asthma (not for acute relief).
- •History of depression with suicidal ideation.
Drug Interactions
CYP3A4/1A2 Inducers (e.g., Rifampicin, Phenobarbital, Phenytoin)
May significantly decrease Pulmobixan plasma concentrations, reducing efficacy. Co-administration is generally not recommended.
CYP3A4/1A2 Inhibitors (e.g., Ketoconazole, Erythromycin, Cimetidine)
May increase Pulmobixan plasma concentrations, increasing risk of side effects. Dose adjustment or careful monitoring may be necessary.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms may include severe gastrointestinal disturbances (nausea, vomiting, diarrhea), headache, and dizziness. Treatment is supportive and symptomatic; no specific antidote available. Hemodialysis is unlikely to be effective.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Not recommended during breastfeeding as it is unknown if Pulmobixan is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months from manufacturing date
Availability
Pharmacies and Hospitals nationwide
Approval Status
Approved by DGDA and major regulatory bodies
Patent Status
Patented until 2035
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
